Wysenski Retirement, New Chief Legal Officer Add Another Layer To CF Data-Error Story At Vertex
This article was originally published in The Pink Sheet Daily
Executive Summary
While Wall Street seems to have forgiven Vertex for mistakenly reporting better breathing-improvement data than actually was the case for an experimental cystic fibrosis drug, questions about executives who sold stock before the data correction are raising eyebrows in Congress and at the SEC.
You may also be interested in...
Vertex Gets Quick FDA Approval Of Kalydeco; Prices New CF Drug At $294,000 Per Year
Kalydeco, an oral CFTR potentiator, becomes the first approved drug to address the underlying cause of cystic fibrosis, rather than just treating the disease’s symptoms.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.